Cargando…

Advances in Alzheimer’s Disease Drug Development

Alzheimer’s disease (AD) is the foremost cause of dementia worldwide. Clinically, AD manifests as progressive memory impairment followed by a gradual decline in other cognitive abilities leading to complete functional dependency. Recent biomarker studies indicate that AD is characterized by a long a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rafii, Michael S, Aisen, Paul S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373002/ https://www.ncbi.nlm.nih.gov/pubmed/25857341 http://dx.doi.org/10.1186/s12916-015-0297-4

Ejemplares similares

Recent developments in Alzheimer's disease therapeutics
por: Rafii, Michael S, et al.
Publicado: (2009)

Epigenetic basis of Alzheimer disease
por: Tecalco-Cruz, Angeles C, et al.
Publicado: (2020)

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
por: Singh, J C, et al.
Publicado: (2014)

New treatment modalities in Alzheimer's disease
por: Koseoglu, Emel
Publicado: (2019)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development
por: Zhu, Wei, et al.
Publicado: (2021)

Advances in drug therapy for systemic lupus erythematosus
por: Wallace, Daniel J
Publicado: (2010)

Molecular and Cellular Basis of Neurodegeneration in Alzheimer’s Disease
por: Jeong, Sangyun
Publicado: (2017)

Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer’s disease
por: Wang, Xuechen, et al.
Publicado: (2022)

S1P and the birth of platelets
por: Hla, Timothy, et al.
Publicado: (2012)

Advances in the Development of Antiviral Compounds for Rotavirus Infections
por: Tohmé, María Julieta, et al.
Publicado: (2021)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
por: Li, Yanbai, et al.
Publicado: (2023)

Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease
por: Lasn, H, et al.
Publicado: (2006)

Effect of pesticides on phosphorylation of tau protein, and its influence on Alzheimer’s disease
por: Torres-Sánchez, Erandis D, et al.
Publicado: (2023)

Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development
por: Abd-Rahman, Azrin N., et al.
Publicado: (2022)

Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms
por: Kim, Jaekwang, et al.
Publicado: (2014)

Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor
por: Rao, Zhou-Zhou, et al.
Publicado: (2023)

Predicting the course of Alzheimer’s progression
por: Iddi, Samuel, et al.
Publicado: (2019)

Recent Advances in Catalytic Hydrosilylations: Developments beyond Traditional Platinum Catalysts
por: de Almeida, Leandro Duarte, et al.
Publicado: (2020)

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

Clinical anticancer drug development: targeting the cyclin-dependent kinases
por: Benson, C, et al.
Publicado: (2005)

Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease pathogenesis and treatment
por: Diamantidis, Michael D, et al.
Publicado: (2021)

Genetic tool development underpins recent advances in thermophilic whole‐cell biocatalysts
por: Taylor, M. P., et al.
Publicado: (2011)

Advances in immunotherapy for melanoma
por: Redman, Jason M., et al.
Publicado: (2016)

Recent Advances of the Halogen–Zinc Exchange Reaction
por: Balkenhohl, Moritz, et al.
Publicado: (2020)

Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
por: Di Sessa, Anna, et al.
Publicado: (2021)

ApoE4-Induced Cholesterol Dysregulation and Its Brain Cell Type-Specific Implications in the Pathogenesis of Alzheimer’s Disease
por: Jeong, Woojin, et al.
Publicado: (2019)

Novel drug delivery systems for inflammatory bowel disease
por: Yasmin, Farah, et al.
Publicado: (2022)

Updates in therapeutic drug monitoring in inflammatory bowel disease
por: Lodhia, Nilesh, et al.
Publicado: (2022)

Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease
por: Cassese, Gianluca, et al.
Publicado: (2022)

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
por: Attard, G, et al.
Publicado: (2006)

Current evidence of drug-elution therapy for infrapopliteal arterial disease
por: Spiliopoulos, Stavros, et al.
Publicado: (2019)

Advances in the treatment of chronic myeloid leukemia
por: Eiring, Anna M, et al.
Publicado: (2011)

Elastography-based screening for esophageal varices in patients with advanced chronic liver disease
por: Paternostro, Rafael, et al.
Publicado: (2019)

Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout
por: Nishino, Takeshi, et al.
Publicado: (2014)

Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer’s disease
por: Ikeda, Yuka, et al.
Publicado: (2021)

Recent Advances in the Chemistry of Heavier Group 14 Enolates
por: Haas, Michael
Publicado: (2019)

Advances in translational therapy for locally advanced gastric cancer
por: Zhao, Kai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_22ph5unldr7sa6fkulfo5gssll